BioLineRx (NASDAQ: BLRX) — Perfil da empresa, notícias e dados financeiros
BioLineRx is a biopharmaceutical company focused on oncology, developing therapies for cancer treatment.
BioLineRx
BioLineRx (TLV:BLRX), (NASDAQ:BLRX) is a biopharmaceutical company focused on oncology. The company is dedicated to developing and commercializing a portfolio of products aimed at addressing unmet medical needs in the treatment of cancer. BioLineRx is engaged in advancing a range of therapies from pre-clinical development to advanced clinical trials. Among its key projects is the development of novel therapeutics that target tumor microenvironment and immune checkpoint pathways. The objective of BioLineRx is to improve the outcomes and lives of patients battling cancer by bringing innovative treatments from the laboratory to the clinic. Through strategic collaborations and rigorous research and development, BioLineRx strives to unlock new possibilities in cancer care.
Resumo
Operações
Produtos e/ou serviços de BioLineRx
- Motixafortide (BL-8040) is a novel CXCR4 antagonist for hematological malignancies, stem cell mobilization, and solid tumors.
- AGI-134, a synthetic alpha-Gal immunotherapy for solid tumors, leveraging the body's immune system to target and destroy cancer cells.
- BL-5010 is a non-surgical solution for the removal of skin lesions, offering a convenient alternative to traditional procedures.
- BL-7040, an oral treatment aimed at inflammatory bowel disease, providing relief for patients with conditions like Crohn's disease.
- BL-8020, an oral HCV treatment with a unique mechanism, aiming to inhibit HCV-induced autophagy in infected cells.
- BL-1040, a device for the prevention of cardiac remodeling post-myocardial infarction, aiming to improve heart function and prognosis.
equipe executiva do BioLineRx
- Philip A. SerlinChief Executive Officer
- Mali ZeeviChief Financial Officer
- Ella SoraniChief Development Officer
- John LaceyHead of Corporate Communications & Investor Relations
- Raziel FriedTreasurer & Budgetary Control Director
Últimas notícias sobre a BioLineRx
BioLineRx reports $4.3 million Q2 loss
United StatesBioLineRx and Hemispherian report positive cancer data
United StatesBioLineRx and Hemispherian to showcase preclinical data for first-in-class glioblastoma asset at ASCO 2026
United StatesBioLineRx, Hemispherian disclose promising data for glioblastoma candidate
United StatesHemispherian launches first-in-human trial for glioblastoma therapy GLIX1
United StatesBioLineRx initiates Phase 1/2a trial of GLIX1 for glioblastoma following 2025 financial results
United States
Principais indicadores financeiros
Resultados divulgados pela BioLineRx, em USD.
- Cap. de mercado
- 10 mi
- Receita (TTM)
- 1,4 mi
- P/L
- —
- LPA (diluído, TTM)
- 0.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,2 mi | -10,4 mi | -1,2 mi | |
| 28,9 mi | -20,4 mi | -9,2 mi | |
| 4,8 mi | -49,7 mi | -60,6 mi | |
| 0 | -29,2 mi | -25 mi |